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Summary Twenty-four assessable patients with hormone-resistant prostate cancer (HRPC) were to receive daily doses of oral estramustine
phosphate (EMP), 10 mg kg-1, and intravenous epirubicin (EPR) infusions, 100 mg m-2, every third week up to a cumulative dose of
500 mg m-2. Biochemical response [. 50% reduction in pretreatment serum prostate-specific antigen (PSA) after three cycles of 2 3 weeks'
duration] was demonstrated in 13 of 24 patients included (54%). No objective response (WHO criteria) was observed, although seven of nine
evaluable patients achieved a . 50% serum PSA reduction. Subjective improvement (pain score, performance status) occurred in 7 of 24
patients, whereas nine patients progressed subjectively. There was no correlation between subjective and biochemical response.
Biochemical progression (. 50% increase of nadir PSA) occurred after a median of 12 weeks. All but two patients were alive after a median
follow-up time of 8.7 months for surviving patients (range 3.3-13.2). Eight patients experienced grade 3/4 leucopenia, with no indication of
cumulative myelosuppression. Cardiovascular toxicity was experienced by four patients. Two patients developed angioedema twice, in one
patient requiring hospitalization at the intensive ward. Based on this limited series, the combination of EPR and EMP in patients with HRPC is
tolerable and appears to be effective in terms of significant PSA reduction. The results warrant further investigations of the two drugs and, in
particular, of the clinical significance of . 50% PSA decrease in patients with HRPC.
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Metastatic prostate cancer progressing during androgen-suppres-
sive treatment represents a therapeutic dilemma. No consensus
exists on the optimum medical treatment of this condition, which
conventionally comprises progressive disease in spite ofcastration
levels of serum testosterone. The median survival of symptomatic
patients with hormone-resistant prostate cancer (HRPC) is 8-
10 months (Foss'a et al, 1992a; Newling et al, 1993). Androgen
independence most probably reflects the selection of hormone-
resistant cell clones.
The lack of objective assessable response parameters has been
the major obstacle to the development ofnew treatment modalities
in HRPC. Sclerotic bone metastases, increased uptake on bone
scans and the primary tumour are all unsuitable measures of treat-
ment response (Jones et al, 1986; Smith et al, 1990), and patients
with bidimensionally measurable metastatic lesions represent a
minority. Furthermore, it has been claimed that the tumour biology
of these patients may differ from that in patients with skeletal
metastases. After the introduction of prostate-specific antigen
(PSA) in the management of previously untreated prostate cancer,
this tumour marker has increasingly been used in patients with
HRPC. However, the clinical role of PSA in HRPC may differ
from that in patients before and during primary hormone treatment.
Estramustine phosphate (EMP) has been used in the treatment
ofprostate cancer for many years. This nomitrogen mustard carba-
mate derivative ofoestradiol-1713 phosphate displays both oestro-
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genic and cytotoxic activities without leading to bone marrow
suppression. In vitro EMP inhibits polymerization ofmicrotubules
by interaction with tubulin-binding domains of microtubule-
associated proteins (MAPs), thereby inhibiting the cytoskeletal
networks contributing to cell motility and cell division (Steams et
al, 1988; Dahll0fet al, 1993). Promising results have recently been
reported for the use of EMP combined with etoposide or vinblas-
tine in the treatment of HRPC (Hudes et al, 1992; Seidman et al,
1992; Pienta et al, 1994).
Epirubicin (EPR), the 4' epimer ofdoxorubicin, is an anthracy-
cline derivative. EPR and doxorubicin have shown some efficacy
in the treatment of HRPC, both as single drug treatment and,
considering doxorubicin, as a part ofcombination treatment.
Based on the efficacy and tolerability of EMP and EPR even in
patients ofhigh age and with limitedhaematopoietic reserves, it was
reasonable to combine the two agents in the treatment of patients
with HRPC. In the present study we deal with the results ofa phase
II study evaluating the combination ofEPR and EMP in HRPC.
PATIENTS AND METHODS
Patients
This multicentre phase II study includes 24 patients with
metastatic prostate cancer progressing during primary hormone
treatment (surgical or medical castration). Patients on medical
castration by LHRH analogues continued this treatment during the
trial, maintaining their serum testosterone within the castration
level. Eligible patients should have a serum PSA . 100 ,ug 1-, or
between 20 and 100 ,ug 1-1 if the level had increased by at least
100% during the preceding 2 months ofsymptomatic progression.
Only patients with a white blood cell (WBC) count . 3 x 109 1-1
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Table 1 Pretreatment patient characteristics



































Previous treatment of prostate cancer
Surgical or medical castration
Second hormone treatment
Radiotherapy
Time from progression on primary hormone
treatment to start chemotherapy (months)
< 4 months
Time from start of primary hormone treatment




































dose reduction of25%. EPR was combined with daily oral EMP at
a dose of 10 mg kg-', given in two doses per day. Patients were
instructed to avoid milk and milk products during EMP treatment.
Furthermore, the capsules should be taken at least I h before or
2 h after meals (Gunnarsson et al, 1990).
The end of the trial was defined as the achievement of the
maximal accumulated EPR dose (500 mg m-2) or the development
of intolerable toxicity and/or objective or subjective progression
(see below). Biochemical progression (see below) did not repre-
sent the course oftrial discontinuation. Treatment after discontinu-
ation ofthe trial drugs was up to the clinician's discretion with the
recommendation to continue single-drug EMP therapy.
Pretreatment and follow-up examinations
At trial inclusion ECG and chest radiography were performed
together with a radioisotope bone scan, which enabled categorization
of the extent of disease (EOD) according to Soloway et al (1988)
(EOD grade 0-4). The clinical examination included assessment of
body weight, performance status and pain score (analgesics not
required = 0, non-narcotics occasionally required = 1, non-narcotics
regularly required = 2, narcotics occasionally required = 3, narcotics
regularly required = 4). In 12 patients with objectively measurable
soft-tissue lesions these were evaluated by clinical or radiological
assessments. All patients underwent haematological tests [haemo-
globin (Hb), WBC andplatelet counts] togetherwith liverand kidney
function tests, determination of serum PSA and serum testosterone.
Serum PSA was measured by an in-house immunofluorometric
assay using two monoclonal antibodies and delayed fluorescence
immunoassay technique. The assay is run on a Wallac 1235
AutoDelfia analyser, has a sensitivity better than 0.1 gg 1-', and a
between-assay coefficient of variation below 5%. The assay was
standardized against Hybritec Tandem-R (Wahre et al, 1992).
Regular follow-up examinations were performed 3 weeks after
each EPR infusion and every sixth week after discontinuation of
EPR, or until the development of objective or subjective progres-
sion (see below). Thereafter, patients went off-study, followed up
by general practitioners or local hospitals. Progress forms were
sent to the Norwegian Radium Hospital. At each regular follow-up
the clinical examination and haematological and biochemical tests
were repeated. The haematological status was also controlled on
day 8 and 15 ofeach cycle. Radiological or clinical measurements
of soft-tissue metastases were repeated after three cycles of treat-
ment. The ECG was repeated ifclinically indicated.
'Median; 2range.
and a platelet count > 100 x 109 1-1 were included. Other major
eligibility criteria were performance status < grade 2 (WHO
criteria), no major cardiovascular dysfunction assumed to preclude
the use of the trial drugs, no previous systemic chemotherapy and
the patient's written and verbal informed consent. The protocol
was approved by the Regional Ethical Committee of Health
Region II, Norway.
Therapeutic regimen
Epirubicin was administered intravenously in a slowly running
saline drip at a dose of 100 mg m-2 every third week. If the WBC
count was < 3.0 x 109 1-1 on day 22 of a cycle and/or the platelet
count < 100 x 1091-', EPR was delayed for 1 week with subsequent
Response evaluation
The main outcome parameter was biochemical response assessed
by . 50% reduction of the pretreatment serum PSA level after at
least three cycles and lasting for at least 3 weeks. Biochemical
progression was defined as increase in the nadir serum PSA level of
. 50%, the serum PSA level at progression being at least 20gg 1-'.
After the completion ofthree cycles, objective response was evalu-
ated according to the WHO criteria (Miller et al, 1981). Beneficial
subjective response (improvement) required the reduction of the
pain score by at least one score and/orimproved performance status
by at least one score without being induced by other palliative
measures. The scores ofperformance status 0 and 1 were combined
when evaluating subjective response, disregarding changes
between these two categories. Subjective progression (deteriora-
tion) comprised increase ofthe respective scores by > 1.
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Table 2 Serum PSA changes 2 50% during combination treatment (no. of patients with 2 50% PSA reduction/no. of evaluable patients)
Pretreatment serum PSA (gg I-') After one cycle After three cycles After five or six cyclesa Max. reduction any time
< 200 3/8 2/4 0/1 6/8
201-500 2/6 5/6 3/4 5/6
> 500 4/10 6/9 5/5 9/10
Total 9/24 13/19 8/10 20/24
aMaximum cumulative dose (500 mg m-2).
Table 3 PSA changes in patients not fully evaluable for biochemical response (completed fewer than three cycles)
PSA (jig 1-1) EPR discontinued
Patient ID Pretreatment After one cycle After two cycles
6 784 275 (65%)a Subjective progression (1)b
16 132 56 (58%) 25 (81%) Subjective progression (2)
18 101 66 (35%) Subjective progression (1)
19 136 75 (45%) 62 (54%) Toxicity (stable disease) (2)
20 36 14 (61%) Toxicity (stable disease) (1)
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Figure 1 Time to achievement of nadir PSA in all 24 patients receiving
estramustine phosphate and epirubicin
Toxicity evaluation
Whenever possible the WHO grading system for toxicity was
used. Otherwise toxicity was graded as none, mild, moderate or
severe.
Follow-up
As of 1 June, 1996, the median observation time in surviving
patients was 8.7 months (range 3.3-13.2).
Statistics
Standard statistical methods were used (median, range, chi-
square). Time to biochemical progression (calculated from the
time when the patient's nadir was reached) and crude survival
were assessed according to the Kaplan-Meier procedure. A P-
value of < 0.05 indicated statistical significance.
RESULTS
Patients
A total of 24 patients entered the trial between April 1995 and
January 1996. The performance status was 0 or I in 21 patients.
Ten patients did not experience pain due to their metastatic lesions.
Other pretreatment patient characteristics are summarized in Table
1. Sixteen patients had pretreatment PSA levels of > 200 ,ug 1-1.
Nineteen patients were fully evaluable for biochemical response.
In the remaining five patients trial treatment was discontinued
because ofsubjective progression (three patients) or due to intoler-
able toxicity (two patients) after one or two cycles. Nine of the 12
patients who initially presented with measurable soft tissue metas-
tases had sufficient follow-up examinations for assessment of
objective response. All 24 patients were assessable for subjective
response and toxicity.
Treatment
A total of 92 cycles of combined EPR and EMP treatment were
administered with a median offour cycles perpatient (range 1-6).
Nineteen patients received at least three cycles and ten patients had
five or six cycles.
Thirteen of the 24 patients included (54%) demonstrated
biochemical response with a 2 50% serum PSA decline after three
cycles. In six patients the pretreatment PSA level was reduced by
> 75%. Biochemical response was seen equally often in patients
with baseline PSA of < 200 gg 1-', 201-500 ,ug 1-1 or > 500 gg 1-'
(Table 2). Four out of five patients who received fewer than three
cycles demonstrated a . 50% serum PSA reduction after one or
two cycles (Table 3). PSA continued to decrease after three cycles
in the ten patients who continued trial treatment to five or six
cycles. The serum PSA nadirfor all 24 patients was reached after a






















Figure 2 (A) Percentage PSA reduction and objective response in nine
evaluable patients with measurable soft-tissue metastases and pretreatment
PSA values of < 200 ,ug 1-1 (E), 201-500 ug 1-' (A) and > 500 jg 1-1().
(B) Percentage PSA reduction and subjective response in 24 patients
receiving estramustine phosphate and epirubicin, with pretreatment PSA
values of < 200 ,ug 1-1 (E), 201-500 jig 1-' (A) and > 500 gg 1-' (V)
Table 4 Haematological toxicity
WHO grade Not Total Number of
available patients with
grade 3/4 toxicity
0 1 2 3 4
WBC 38a 10 20 13 5 6 92 8
Platelets 75 4 1 5 1 6 92 2
aNumber of cycles with toxicity.
Table 5 Non-haematological toxicity
No. of patients
Angioedema 2a
Chills with or without fever 5









Mucositis, grade 2 4




Deep venous thrombosis 1





aLife-threatening in one patient.
and nine patients progressed subjectively, whereas the condition
remained clinically stable in eight patients.
Survival
median of 12 weeks (range 2-31) (Figure 1). Time from start of
last treatment cycle to PSA nadir was median 3.2 weeks (range -7
to 14). The only patient who obtained PSA nadir more than 10
weeks after the last EPR infusion continued EMP treatment
after discontinuation of trial treatment. Biochemical progression
was observed in 17 of 19 who were patients fully evaluable of
biochemical response after a median of 12 weeks (range 3-27).
The observed PSA changes were not correlated with objective
or subjective response, independent of the initial PSA level
(Figure 2A and B). No complete or partial response was observed
in the nine evaluable patients with soft tissue metastases. In seven
of these nine patients, the pretreatment serum PSA declined by at
least 50%. Seven patients experienced subjective improvement
At the end of the observation time two patients were dead of
prostate cancer. The overall survival rate after 6 months' observa-
tion time was 96%.
Toxicity
Eighteen of the 92 cycles of EPR were associated with the occur-
rence of grade 3/4 leucopenia (eight patients), and 6 cycles with
grade 3/4 thrombocytopenia (two patients) (Table 4). The event of
grade 3/4 myelosuppression was not related to the pretreatment
EOD grade of the bone scan or the patient's age. There was no
evidence ofcumulative bone marrow suppression. All non-haema-
tological adverse effects observed during the trial are presented in
Table 5. Alopecia grade 3 was experienced by all 24 patients.
Despite prophylactic antiemetic treatment with 5-HT3 receptor
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Table 6 Examples of serum PSA changes in HRPC patients during clinical trials.
Reference Drug(s) Dose(s) Patients with > 50% PSA decline
Yagoda et al (1993) EMP 14 mg kg-' day-' 9/42 (21%)
Brausi et al (1995) Epirubicin 100 mg m-2 every 3 weeks 8/25 (32%)
FossS et al (1994) EMP 560-700 mg day' 4/12 (33%)
Pienta et al (1994) EMP + etoposide 15 mg kg-' day' + 50 mg m-2 day-' 22/42 (52%)
van Rijswijk et al (1992) Suramin Serum concentration 150-200 mg 1-' 14/27 (52%)
Seidman et al (1992) EMP + vinblastine 10 mg kg-' day' + 4 mg m-2 week-' 13/24 (54%)
Eisenberger et al (1995) Suramin Serum concentration 100-300 gg ml-' 40/67 (60%)
Hudes et al (1992) EMP + vinblastine 600 mg m-2 day-' + 4 mg m-2 week-' 22/36 (61%)
Present study EMP + epirubicin 10 mg kg-' day' + 100 mg m-2 every 3 weeks 13/19 (68%)
antagonists, 16 patients suffered from grade 2 nausea for 1-3 days
after the EPR infusions. One patient was hospitalized because of
grade 3 vomiting. Twelve patients developed gynaecomastia, five
with painful enlargement ofthe breasts. Four patients experienced
cardiovascular toxicity, one patient with a deep venous throm-
bosis, two with arrhythmia and the last patient developed dysp-
noea and vertigo, most probably secondary to cardiomyopathy.
Three of these four patients required hospitalization because of
cardiovascular toxicity. Spontaneously reversible chills with or
without a rise in temperature were reported by five patients who
experienced this side-effect 3-4 h after EPR infusion. Two patients
developed angioedema twice. In one patient the last event was
life-threatening. This patient concomitantly used Renetic, an
angiotensin-converting enzyme (ACE) inhibitor.
Seven cycles were delayed, four because of toxicity (mucositis
or myelosuppression). Four EPR infusions were given with dose
reduction.
DISCUSSION
Multiple clinical trials have evaluated the efficacy of new agents
and new drug combinations in HRPC (Eisenberger et al, 1985). As
in the present study, some agents or drug combinations have
shown promising activity in phase II studies, but without life-
prolonging effect of treatment. The results from such trials should
be transferred to routine practice with caution. Furthermore, there
may be differences between the experience in America and
Europe, and between medical oncologists and urologists.
American trial patients with HRPC are often positively selected
younger individuals with little or no pain, a good performance
status, adequate bone marrow and kidney function and limited
tumour volume. The majority of HRPC patients seen in routine
urological practice in Europe, however, suffer from severe
metastatic bone pain, display a decreased general condition and
co-morbidity and have often reduced bone marrow function due to
high age and metastatic involvement. These general limitations
and selection bias are also valid for the present study. Of the 24
patients included, 21 had performance status 0/1 and ten patients
did not use any analgesics despite progressive metastatic prostate
cancer. In comparison, in a joint study from the Royal Marsden
Hospital, London, and the Norwegian Radium Hospital, Oslo,
among patients with HRPC referred for palliative treatment only
40% displayed a performance status of 0/1 and pain was a clinical
problem in 78% ofthem (Foss'a et al, 1992a). Furthermore, halfof
all patients in the present study presented metastatic soft-tissue
lesions, whereas such metastatic involvement is usually present
in only 10-15% of patients with advanced prostatic cancer. The
positive selection of our patients also becomes evident by the
favourable 6-month survival of 96%, whereas the comparable
percentage of untreated patients referred for palliative radio-
therapy ofskeletal metastases was 60% (Foss'aet al, 1992a). When
evaluating trial results it is important to take into account such
selection biases as they may mirror different tumour biology in
trial patients compared with non-trial patients.
The extended use ofPSA as a serum tumour marker in diagnosis
and during follow-up of prostate cancer has led to the increasing
application of this tumour marker during the management of
HRPC. As in the present study, a . 50% reduction in pretreatment
serum PSA has been the primary objective ofmany trials (Table 6)
(Hudes et al, 1992; Seidman et al, 1992; van Rijswijk et al, 1992;
Yagoda et al, 1993; Foss'a et al, 1994; Pienta et al, 1994; Brausi et
al, 1995; Eisenberger at al, 1995). The significance of serum PSA
as a tumour marker for prognosis and tumour response in HRPC
may, however, be questioned. Foss'a et al (1992c) was not able to
establish the prognostic significance ofdifferent serum PSA levels
in patients with symptomatic HRPC. In the present study no corre-
lation was detected between biochemical and objective response,
as also observed by other authors (Seidman et al, 1992; Yagoda et
al, 1993). Admittedly only nine patients were evaluable. These
clinical data are consistent with in vitro observations: PSA
production and secretion are androgen dependent, and androgen
deprivation may lead to decrease ofPSA production without corre-
sponding cell death (Csapo et al, 1988; Rocca et al, 1991; Gleave
et al, 1993). Despite the lack of relationship between biochemical
and objective response in our and other studies, a relation between
treatment-associated PSA reduction and favourable survival in
patients with HRPC has been demonstrated (Kelly et al, 1993;
Thibault et al, 1993). This can, however, be explained by the possi-
bility that PSA reduction is most often obtained in patients with a
biologically less aggressive disease and favourable survival rates
independent ofthe PSA decrease. Further large clinical studies are
needed to evaluate the role of PSA and its components (free vs
bound PSA) as a tumour marker in HRPC. In addition, PSA reduc-
tions should be related to known pretreatment parameters (such as
performance status, alkaline phosphatase, lactate dehydrogenase,
haemoglobin, duration of hormone dependency; Foss'a et al,
1992b) in order to establish the independent significance of PSA
reduction.
EMP is usually categorized as a cytotoxic agent with no or
limited myelotoxicity. Dependent on selection criteria of the
patients and the definition of response criteria, EMP has shown
variable response rates (Benson et al, 1986). In the clinical situa-
tion it has been difficult to prove the cytotoxic effect ofsingle-drug
EMP therapy (Newling et al, 1993; Fossa et al, 1990), whereas the
British Joumal of Cancer (1997) 76(1), 93-99 C Cancer Research Campaign 199798 EH Hernes etal
results ofrecent trials combining EMP with etoposide and vinblas-
tine are more promising (Hudes et al, 1992; Seidnian et al, 1992;
Pienta et al, 1994). The concomitant use of EPR precludes any
statement about EMP-induced bone marrow suppression in our
trial. The previously described oestrogenic effect ofEMP (Benson
et al, 1990) also became evident in the present study, in which 12
patients developed gynaecomastia, five of them with painful
breast enlargement. Based on clinical observations one has to
consider the possibility that high-dose EMP, as used in the present
study, may display its main activity by high oestrogen levels.
High-dose oestrogen treatment is a therapeutic modality known to
be effective in prostate cancer patients progressing after primary
androgen-suppressive treatment (Smith et al, 1986; Pavone-
Macaluso et al, 1986). Many of these patients, including some
from the present study, may virtually still be hormone dependent
though androgen independent.
EPR in a low-dose regimen has been explored by several inves-
tigators. The EORTC Genitourinary Group (protocol 30841) used
EPR 12 mg m-2 weekly with an objective response rate (complete
or partial) of only 12% (Jones et al, 1987). Francini et al (1993)
presented a 37.7% response rate (bone scan, soft-tissue metas-
tases, acid phosphatase, weight, symptoms and performance
status) after EPR 30 mg m-2 weekly, and Elomaa et al (1991)
demonstrated improved performance status in 69% of patients
using EPR at 25 mg m-2 weekly. In order to increase efficacy, but
still within a level of tolerable toxicity, higher doses of EPR have
been tested. Brausi et al (1995), tested EPR 100 mg m-2 intra-
venously every 3 weeks, with the results of 24% partial response
and 42% stable disease according to WHO criteria. The same
dosage schedule was employed in the present study and found to
be tolerable in the majority of trial patients. However, a further
increase in dose in future EPR combination regimens is not recom-
mended. Reductions of single doses may, on the contrary, be
preferable in clinical use, allowing prolonged periods of treatment
before reaching the maximal cumulative dose of500 mg m-2.
The haematological toxicity was unpredictable, but generally
within acceptable levels. However, as many as eight patients devel-
oped grade 3/4 leucopenia, one patient requiring hospitalization.
The non-haematological side-effects were generally well tolerated
and not dose related. Four patients presented symptoms of cardio-
vascular toxicity; in three patients their condition required hospi-
talization. 'Chills', as experienced by five of our patients, should
be viewed on the background of previously reported temperature
rise associated with high-dose EPR (Ganzina et al, 1983; Martoni
et al, 1990; Brausi et al, 1995). Although the development of
angioedema in one oftwo patients was related in time to EPR infu-
sions, it was most probably related to the use of EMP. Pienta et al
(1994) reported allergic reactions with rash and tongue swelling in
three patients during combined EMP (15 mg kg') and etoposide
therapy. The occurrence of angioedema during EMP treatment
may be related to the high doses ofthis drug and/or associated with
the simultaneous use of other drugs which increase the risk ofthis
side-effect, for instance ACE inhibitors (Hedner et al, 1992).
In this limited series ofpatients with HRPC the combination of
high-dose EPR and EMP appears to be effective in achieving
serum PSA reduction by > 50%. The treatment is generally well
tolerated, but grade 3/4 bone marrow depression may occur. The
risk of angioedema should not be overlooked when using high-
dose EMP in patients with HRPC. Our results warrant further
exploration of the clinical significance of PSA changes during the
treatment of patients with HRPC.
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